Here’s a bold statement: The future of medicine might just hinge on a tiny element like boron. But here’s where it gets controversial—can a single chemical platform revolutionize treatments for some of the world’s most challenging diseases? AN2 Therapeutics, Inc. (Nasdaq: ANTX) is betting on it, and they’re ready to share their vision. The Menlo Park-based biopharmaceutical company, known for its groundbreaking boron chemistry platform, has announced that Eric Easom, its Co-Founder, Chairman, President, and CEO, will take center stage at the 8th Annual Evercore HealthCONx Conference, held from December 2-4, 2025. This isn’t just another industry event—it’s a chance to peek into the future of drug development.
On Wednesday, December 3, 2025, at 10:50 AM ET, Easom will engage in a fireside chat, offering insights into AN2’s innovative approach to creating small molecule therapeutics. And this is the part most people miss—boron, often overlooked, is at the heart of their pipeline, targeting diseases like Chagas, melioidosis, and NTM lung disease caused by M. abscessus. But that’s not all—AN2 is also making waves in oncology and other infectious diseases. The event will be webcast live on the Investors section of their website (www.an2therapeutics.com), with a replay available for 30 days afterward. Plus, members of the management team will be available for one-on-one meetings, offering a rare opportunity to dive deeper into their work.
So, why does this matter? AN2 Therapeutics is committed to tackling critical medical needs with high-impact drugs, aiming to improve health outcomes globally. Their boron-based compounds aren’t just experimental—they’re a potential game-changer. Here’s the thought-provoking question: Could this approach redefine how we treat infectious and oncological diseases? Weigh in below—do you think boron chemistry is the next big thing in medicine, or is it too early to tell? Let’s spark a conversation!
